Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Centre For Virology Vaccinology And Therapeutics Limited has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 3 art units, indicating examiner diversity with some concentration at the art-unit level.
MATALKAH, FATIMAH KHALAF is the busiest examiner, with 1 pending matter. No examiner accounts for multiple listed matters, so counsel should organize prosecution by matter and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18058169 | VIRAL NUCLEIC ACID MOLECULES, AND COMPOSITIONS AND METHODS OF USE THEREOF | KINSEY WHITE, NICOLE ERIN | 23d overdue |
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 18546895 | ANTI-VIRAL PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | KOMATSU, LI N | — |
| 18350402 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | MIKNIS, ZACHARY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18058169 | VIRAL NUCLEIC ACID MOLECULES, AND COMPOSITIONS AND METHODS OF USE THEREOF | KINSEY WHITE, NICOLE ERIN | 23d overdue |
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | MATALKAH, FATIMAH KHALAF | — |
| 18546895 | ANTI-VIRAL PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | KOMATSU, LI N | — |
| 18350402 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1638 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18546895 | ANTI-VIRAL PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | KOMATSU, LI N | 1658 | §101§102§112DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18350402 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | MIKNIS, ZACHARY J | 1658 | §102§112 | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18058169 | VIRAL NUCLEIC ACID MOLECULES, AND COMPOSITIONS AND METHODS OF USE THEREOF | KINSEY WHITE, NICOLE ERIN | 1672 | §102§103§112 | Final Rejection | 23d overdue | Pending | Nov 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre For Virology Vaccinology And Therapeutics Limited has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Fatimah Khalaf Matalkah has the most, with 1 of Centre For Virology Vaccinology And Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
